about
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsGeneration of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.Olmutinib-induced palmoplantar keratoderma.A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.Olmutinib Induced Lichen Planus Like EruptionOlmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 andOlmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
P2860
Q28069708-842164AB-7A0C-4F59-9B00-A741B7B8086CQ33829488-51AD2C40-D57C-4F13-837E-EB558376037AQ34550460-1FBE9AE0-5995-44BC-B9B7-F655DC03D374Q39254692-B7CC3E34-B9ED-4085-9376-523ED2014EB5Q48132766-57DFC948-551F-4D26-87E9-2F3E47D1CB05Q48500283-9BA768B3-3734-4307-8BDD-B2B8816C1008Q49315568-3035E029-EC65-44F1-AD54-3D23F01EF806Q49720695-BCA8574C-8AD5-482E-8960-1E5544800061Q50345931-3C9C8764-1937-4A62-BCE2-5236AB133DA7Q52591096-4C478CEF-47FF-43B6-848A-442624B7AAC5Q57210987-85470B51-0BCE-4518-8727-49D892B8E257Q57211312-FB823A5E-C3AD-4273-BF22-C8021BA56F72Q57816977-D3156343-D1FC-4C6F-8420-A103F7EDE06E
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Olmutinib: First Global Approval.
@en
Olmutinib: First Global Approval.
@nl
type
label
Olmutinib: First Global Approval.
@en
Olmutinib: First Global Approval.
@nl
prefLabel
Olmutinib: First Global Approval.
@en
Olmutinib: First Global Approval.
@nl
P2860
P1433
P1476
Olmutinib: First Global Approval.
@en
P2093
Esther S Kim
P2860
P2888
P304
P356
10.1007/S40265-016-0606-Z
P577
2016-06-29T00:00:00Z